23 Mar 2026

IP Group:'Call option' on Pfizer’s anti-obesity programme

IP Group plc (IPO:LON) | 59.6 0.7 1.9% | Mkt Cap: 526.5m

- Dan Ridsdale | Milosz Papst
- 3 pages

We believe that IP Group’s shares currently offer a compelling asymmetric return profile stemming from its exposure to potential future income streams from the anti-obesity products of Metsera (acquired by Pfizer in November 2025 for up to $10bn). Reflecting IP Group’s listed holdings (primarily Ox

Sign up for free to access

Get access to the latest equity research in real-time from 12 commissioned providers.

IP Group:'Call option' on Pfizer’s anti-obesity programme

IP Group plc (IPO:LON) | 59.6 0.7 1.9% | Mkt Cap: 526.5m

Published: 23 Mar 2026
Author: Dan Ridsdale | Milosz Papst
Pages: 3

We believe that IP Group’s shares currently offer a compelling asymmetric return profile stemming from its exposure to potential future income streams from the anti-obesity products of Metsera (acquired by Pfizer in November 2025 for up to $10bn). Reflecting IP Group’s listed holdings (primarily Ox